MARKET WIRETradingView • 18h ago
ADRX Forecast — Price Target — Prediction for 2027TradingView report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
Why ADRX Stock dropped -4.76% Today — RQD Quant Desk Flash
$17.00 -4.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $16.82
ADARx Pharmaceuticals Inc. (ADRX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.82B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ADRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ADRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, ADARx Pharmaceuticals Inc. (NASDAQ: ADRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $17.00 (-4.76% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ADRX ranks #287 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ADRX compare to AGIO and ZBIO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADRX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AGIO (Agios Pharmaceuticals Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -33.8%, cap $1.82B) and ZBIO (Zenas BioPharma Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, ADRX leads on earnings multiple (N/A) while AGIO leads on capital efficiency (-33.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ADRX?
▼
For ADARx Pharmaceuticals Inc. (ADRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #287 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $16.82 (-1.05%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.3% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY ADRX SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)
SEC XBRL Trailing 12 Months: 1.3% FCF Margin ($50.8M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$17.97-1.9% Next Q
56
Q2 (-2Q)Grade C-$17.63+1% Next Q
53
Q3 (-1Q)Grade C-$17.81-4.5% Next Q
51
CurrentGrade D$17.00-5.6% Hist 90D α
48
Trajectory: C (56) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ADRX Turnaround Squeeze
While ADRX currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.12) and Max Pain ($17.85) forces dealer call-delta covering toward $24.37.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ADRX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ADRX Stock dropped -4.76% Today — RQD Quant Desk Flash
ADARx Pharmaceuticals Inc. (ADRX) dropped -4.76% to $17.00, trading at 17% of its 52-week range ($15.71 – $23.21). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 17% of its 52-week range ($15.71 – $23.21) with RSI-14 at 29.7 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $17.00 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $50.8M annual free cash flow.
Live ADRX Headlines & Catalysts
MARKET WIREInvesting.com • 21h ago
UBS initiates ADARx Pharmaceuticals stock with buy rating on siRNA platformInvesting.com report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Incyte (INCY) and ADARx Pharmaceuticals (ADRX)The Globe and Mail report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
ADRX|ADARx Pharmaceuticals Ord Shs|Price:18.130|Chg%:+0.320TradingKey report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
CATALYSTMarketBeat • 1d ago
ADARx Pharmaceuticals (NASDAQ:ADRX) Upgraded to Hold at Zacks ResearchMarketBeat report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
CATALYSTRTTNews • 1d ago
ADARx Pharmaceuticals (ADRX): Can Its SiRNA Pipeline Unlock Multiple Growth Opportunities?RTTNews report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
ADARx Pharmaceuticals Ord Shs (ADRX) Income StatementTradingKey report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
US Analyst Updates — October 20th, 2026The Globe and Mail report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 13d ago
TD Cowen Initiates Coverage On Adarx Pharmaceuticals with Buy RatingTD Cowen analyst Tyler Van Buren initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating.
MARKET WIREBenzinga • 13d ago
JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38JP Morgan analyst Tessa Romero initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $38.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADRX)
- ✓Walkthrough of ADRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ADRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.14%🛡️ HOLDING TREND SUPPORT
2026-11-02O $16.95H $17.03L $15.71C $17.00VOL 378.6K
RES: $19.21SUP: $16.58SMA50: $18.12
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ADRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ADRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ADRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ADRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADRX)
Health Care Rank #287 of 1016
⚔️ AGIO vs ADRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ADRX vs. AGIO, ZBIO, GENB, TRAX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ADARx Pharmaceuticals Inc. (ADRX) ranks #287 by composite RQD confidence (48/100, grade D) and #273 by equity capitalization ($1.82B). Within this direct 5-issuer industry benchmark cohort, ADRX leads on earnings valuation at N/A trailing P/E, while AGIO leads on capital efficiency and profitability with -33.8% ROIC and 88.3% gross margin. GENB currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with ADRX at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ADRX
ACTIVE
ADARx Pharmaceuticals Inc. | D | 48/100 | — | — | — | -4.76% | $1.82B | Benchmark Subject |
| AGIO Agios Pharmaceuticals Inc. | D- | 35/100 | — | 88.3% | -33.8% | -17.94% | $1.82B | /agio-vs-adrx → |
| ZBIO Zenas BioPharma Inc. | D- | 38/100 | — | — | -35.0% | -1.29% | $1.85B | /zbio-vs-adrx → |
| GENB Generate Biomedicines Inc. | D+ | 52/100 | — | — | — | -8.31% | $1.86B | /genb-vs-adrx → |
| TRAX First Tracks Biotherapeutics Inc. | D | 44/100 | — | — | -35.0% | -0.32% | $1.89B | /trax-vs-adrx → |
2. ADRX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTADARx Pharmaceuticals Inc. (ADRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.82B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. ADRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ADRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, ADARx Pharmaceuticals Inc. (NASDAQ: ADRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $17.00 (-4.76% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ADRX ranks #287 in composite RQD confidence.
How does ADRX compare to AGIO and ZBIO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADRX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AGIO (Agios Pharmaceuticals Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -33.8%, cap $1.82B) and ZBIO (Zenas BioPharma Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, ADRX leads on earnings multiple (N/A) while AGIO leads on capital efficiency (-33.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ADRX?
For ADARx Pharmaceuticals Inc. (ADRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #287 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ADRX trading relative to its 50-day, 200-day, and 52-week technical levels?
ADRX last traded at $17.00 (-4.76% on volume of 542,284 shares), positioning the stock -6.18% below its 50-day simple moving average ($18.12) and -6.34% below its 200-day simple moving average ($18.15). Across its 52-week range of $15.71 to $23.21, ADRX sits at the 17.2% percentile with a 14-day RSI of 29.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($14.87 to $19.13).
ADRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ADRX stock moving today?
Why ADRX Stock dropped -4.76% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 48/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ADRX — ADARx Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:12:53Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ADRX carries an RQD Score of 51 and a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
- Fundamental Cash Engine: 12 / 20. The rating cites ROIC of 0% and FCF yield of 0%. For a prospective investor, the cash-generation case is currently unproven in the source data.
- Whale 13F Flow: 5 / 20. Described as institutional accumulation and options positioning. This is the lowest pillar and suggests weak institutional support in the source data.
- Insider Conviction: 9 / 20. Described as SEC Form 4 and Congressional PTR cluster flow. Insider signals are modest per this pillar.
- Macro Regime Fit: 12 / 20. Beta of 1.0 and sector sensitivity are cited. The stock is rated as moving in line with the broader market rather than offering defensive or differentiated behavior.
- Forensic Balance Sheet: 13 / 20. Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5 are cited. This is the strongest pillar, indicating a balance sheet that is more stable than the cash-flow and flow pillars.
Investor implications: the upside case rests on the balance-sheet strength and on the catalyst flow below; the valuation tradeoff is that without reported earnings, cash flow, or P/E data, the rating cannot distinguish between a pre-profit growth profile and a stalled one. The rating's sell label reflects weak cash returns and institutional flow rather than balance-sheet distress.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data.
Open Questions
- What are the reported revenue, operating income, and net income figures, given that the financials section contains no data?
- What is the ADARx siRNA pipeline's clinical stage and timeline, and what does the source identify as its catalysts?
- Why does the rating show ROIC and FCF yield of 0%, and what is the company's path to positive cash generation?
- Which price is current: the market-data price of 17, or the 18.130 print in the TradingKey headline?
- What do the UBS buy initiation and Zacks Hold upgrade rest on, and what are their price targets?
ADRX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for ADARx Pharmaceuticals Inc. (ADRX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 18h ago
ADRX Forecast — Price Target — Prediction for 2027 TradingView report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 21h ago
UBS initiates ADARx Pharmaceuticals stock with buy rating on siRNA platform Investing.com report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Incyte (INCY) and ADARx Pharmaceuticals (ADRX) The Globe and Mail report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
ADRX|ADARx Pharmaceuticals Ord Shs|Price:18.130|Chg%:+0.320 TradingKey report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST MarketBeat • 1d ago
ADARx Pharmaceuticals (NASDAQ:ADRX) Upgraded to Hold at Zacks Research MarketBeat report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST RTTNews • 1d ago
ADARx Pharmaceuticals (ADRX): Can Its SiRNA Pipeline Unlock Multiple Growth Opportunities? RTTNews report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
ADARx Pharmaceuticals Ord Shs (ADRX) Income Statement TradingKey report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
US Analyst Updates — October 20th, 2026 The Globe and Mail report covering ADARx Pharmaceuticals Inc. (ADRX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ADRX Bull vs. Bear Conversation Board — What's Your Call at $17.00?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ADRX 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $18.36 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ADRX (D • RQD 51/100) a Buy at $17.00?
Welcome to the ADRX (ADARx Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 51/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $14.28 (-16.0%)
Spot @ $17.00 Pump the brakes on ADRX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ADRX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ADARx Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $21.08 (+24.0%)
Spot @ $17.00 ADRX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ADRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $17.00 (52-wk range $16.30 - $23.21), any beat on forward guidance forces shorts and underweight funds to chase.